Laurence Albigès, MD, PhD, on the Potential Impact of Immunotherapy-Based Combinations in Advanced RCC

Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, who spoke with CancerNetwork® during the 2022 Genitourinary Cancers Symposium highlighted how treatment with immunotherapy-based combinations have had an impact on the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

In particular, she referenced the improved overall survival (OS) benefit evident with this treatment strategy across the population, as well as a need for a personalized approaches to treating patients.


The first-line landscape has evolved greatly over time and we now have a standard of care combination approach in all our patients for clear cell RCC in the frontline. What we see is that we are impacting OS in our patients. These trials [involving immunotherapy-based combinations] have changed the landscape and the expected OS benefit for our patients. We moved from a median of about 24 months to now 48 months, if we think about nivolumab plus ipilimumab, [for example]. We have greatly increased the overall survival of our patients. This is impacting our treatment strategy in all countries where we have access to different regimens. We now need to tailor [treatment] a bit more to define what combination is most appropriate for [an individual] patient.


Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352